Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Drug Discovery Today
|
January 25, 2012
Should medicinal chemists do molecular modelling?
Timothy J Ritchie, Iain M McLay
Drug Discovery Today
|
January 28, 2014
How drug-like are 'ugly' drugs: do drug-likeness metrics predict ADME behaviour in humans?
Timothy J Ritchie, Simon J F Macdonald
European Journal of Medicinal Chemistry
|
November 7, 2016
Heterocyclic replacements for benzene: Maximising ADME benefits by considering individual ring isomers
Timothy J Ritchie, Simon J F Macdonald
Drug Discovery Today
|
November 16, 2010
The graphical representation of ADME-related molecule properties for medicinal chemists
Timothy J Ritchie, Peter Ertl, Richard Lewis
Drug Discovery Today
|
September 5, 2009
The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design?
Timothy J Ritchie, Simon J F Macdonald
Journal of Medicinal Chemistry
|
May 27, 2014
Physicochemical descriptors of aromatic character and their use in drug discovery
Timothy J Ritchie, Simon J F Macdonald
Journal of Chemical Information and Modeling
|
March 12, 2009
Analysis of the calculated physicochemical properties of respiratory drugs: can we design for inhaled drugs yet?
Timothy J Ritchie, Christopher N Luscombe, Simon J F Macdonald
Drug Discovery Today
|
December 7, 2010
The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types
Timothy J Ritchie, Simon J F Macdonald, Robert J Young, et al.
Journal of Medicinal Chemistry
|
September 3, 2004
Potent and orally bioavailable non-peptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide core
Timothy J Ritchie, Edward K Dziadulewicz, Andrew J Culshaw, et al.
Journal of Medicinal Chemistry
|
May 17, 2002
Nonpeptide bradykinin B2 receptor antagonists: conversion of rodent-selective bradyzide analogues into potent, orally-active human bradykinin B2 receptor antagonists
Edward K Dziadulewicz, Timothy J Ritchie, Allan Hallett, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Drug Discovery Today
|
January 25, 2012
Should medicinal chemists do molecular modelling?
Timothy J Ritchie, Iain M McLay
Drug Discovery Today
|
January 28, 2014
How drug-like are 'ugly' drugs: do drug-likeness metrics predict ADME behaviour in humans?
Timothy J Ritchie, Simon J F Macdonald
European Journal of Medicinal Chemistry
|
November 7, 2016
Heterocyclic replacements for benzene: Maximising ADME benefits by considering individual ring isomers
Timothy J Ritchie, Simon J F Macdonald
Drug Discovery Today
|
November 16, 2010
The graphical representation of ADME-related molecule properties for medicinal chemists
Timothy J Ritchie, Peter Ertl, Richard Lewis
Drug Discovery Today
|
September 5, 2009
The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design?
Timothy J Ritchie, Simon J F Macdonald
Journal of Medicinal Chemistry
|
May 27, 2014
Physicochemical descriptors of aromatic character and their use in drug discovery
Timothy J Ritchie, Simon J F Macdonald
Journal of Chemical Information and Modeling
|
March 12, 2009
Analysis of the calculated physicochemical properties of respiratory drugs: can we design for inhaled drugs yet?
Timothy J Ritchie, Christopher N Luscombe, Simon J F Macdonald
Drug Discovery Today
|
December 7, 2010
The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types
Timothy J Ritchie, Simon J F Macdonald, Robert J Young, et al.
Journal of Medicinal Chemistry
|
September 3, 2004
Potent and orally bioavailable non-peptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide core
Timothy J Ritchie, Edward K Dziadulewicz, Andrew J Culshaw, et al.
Journal of Medicinal Chemistry
|
May 17, 2002
Nonpeptide bradykinin B2 receptor antagonists: conversion of rodent-selective bradyzide analogues into potent, orally-active human bradykinin B2 receptor antagonists
Edward K Dziadulewicz, Timothy J Ritchie, Allan Hallett, et al.
Page
of 2